GlassScriptPhysician profile
Cara P Cook
NPI 1679556336
$7,356.23
in general payments reported to CMS, 2019-2025
49 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,827 · 2022: $1,697 · 2023: $1,655 · 2024: $1,029 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789 · Education: $25.00 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.51 |
| Education | $25.00 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.97 | 2021-2025 | |
| Abbott Laboratories | $1,267.40 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $764.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $417.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $331.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $285.80 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $251.55 | 2021-2025 | Trintellix, Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.25 | 2021-2024 | Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $217.57 | 2024-2025 | Voquezna |
| Amgen INC. | $180.67 | 2021-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $176.59 | 2021-2025 | Belsomra, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $156.37 | 2021-2023 | |
| Genentech USA, INC. | $128.00 | 2021-2022 | |
| Galderma Laboratories, L.P. | $127.84 | 2025 | |
| Amarin Pharma, INC. | $126.39 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.